Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein

被引:46
作者
Hur, Jingyung
Bell, Daphne W.
Dean, Kathleen L.
Coser, Kathryn R.
Hilario, Pablo C.
Okimoto, Ross A.
Tobey, Erica M.
Smith, Shannon L.
Isselbacher, Kurt J.
Shioda, Toshi
机构
[1] Massachusetts Gen Hosp, Canc Res Ctr, Dept Tumor Biol, Charlestown, MA 02129 USA
[2] Massachusetts Gen Hosp, Canc Res Ctr, Mol Profiling Lab, Charlestown, MA 02129 USA
[3] Massachusetts Gen Hosp, Canc Res Ctr, Ctr Canc Risk Anal, Charlestown, MA 02129 USA
关键词
D O I
10.1158/0008-5472.CAN-05-3696
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Induction of mRNA for BIK proapoptotic protein by doxorubicin or gamma-irradiation requires the DNA-binding transcription factor activity of p53. In MCF7 cells, pure antiestrogen fulvestrant also induces BIK mRNA and apoptosis. Here, we provide evidence that, in contrast to doxorubicin or gamma-irradiation, fulvestrant induction of BIK mRNA is not a direct effect of the transcriptional activity of p53, although p53 is necessary for this induction. It is known that p53 up-regulated modulator of apoptosis (PUMA) mRNA is induced directly by the transcriptional activity of p53. Whereas gamma-irradiation induced both BIK and PUMA mRNA, only BIK mRNA was induced by fulvestrant. Whereas both fulvestrant and doxorubicin induced BIK mRNA, only doxorubicin enhanced the DNA-binding activity of p53 and induced PUMA mRNA. Small interfering RNA (siRNA) suppression of p53 expression as well as overexpression of dominant-negative p53 effectively inhibited the fulvestrant induction of BIK mRNA, protein, and apoptosis. Transcriptional activity of a 2-kb BIK promoter, which contained an incomplete p53-binding sequence, was not affected by fulvestrant when tested by reporter assay. Fulvestrant neither affected the stability of the BIK mRNA transcripts. Interestingly, other human breast cancer cells, such as ZR75-1, constitutively expressed BIK mRNA even without fulvestrant. In these cells, however, BIK protein seemed to be rapidly degraded by proteasome, and siRNA suppression of BIK in ZR75-1 cells inhibited apoptosis induced by MG132 proteasome inhibitor. These results suggest that expression of BIK in human breast cancer cells is regulated at the mRNA level by a mechanism involving a nontranscriptional activity of p53 and by proteasomal degradation of BIK protein.
引用
收藏
页码:10153 / 10161
页数:9
相关论文
共 52 条
[1]   Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim [J].
Akiyama, T ;
Bouillet, P ;
Miyazaki, T ;
Kadono, Y ;
Chikuda, H ;
Chung, UG ;
Fukuda, A ;
Hikita, A ;
Seto, H ;
Okada, T ;
Inaba, T ;
Sanjay, A ;
Baron, R ;
Kawaguchi, H ;
Oda, H ;
Nakamura, K ;
Strasser, A ;
Tanaka, S .
EMBO JOURNAL, 2003, 22 (24) :6653-6664
[2]   Comparative effects of Bcl-2 over-expression and ZVAD.FMK treatment on dexamethasone and VP16-induced apoptosis in CEM cells [J].
Benson, RSP ;
Dive, C ;
Watson, AJM .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (05) :432-439
[3]   Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib [J].
Berkers, CR ;
Verdoes, M ;
Lichtman, E ;
Fiebiger, E ;
Kessler, BM ;
Anderson, KC ;
Ploegh, HL ;
Ovaa, H ;
Galardy, PJ .
NATURE METHODS, 2005, 2 (05) :357-362
[4]   THE PROTEIN PHOSPHATASE INHIBITOR OKADAIC ACID INDUCES MORPHOLOGICAL-CHANGES TYPICAL OF APOPTOSIS IN MAMMALIAN-CELLS [J].
BOE, R ;
GJERTSEN, BT ;
VINTERMYR, OK ;
HOUGE, G ;
LANOTTE, M ;
DOSKELAND, SO .
EXPERIMENTAL CELL RESEARCH, 1991, 195 (01) :237-246
[5]   Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (Faslodex, Fulvestrant) [J].
Bouker, KB ;
Skaar, TC ;
Fernandez, DR ;
O'Brien, KA ;
Riggins, RB ;
Cao, DH ;
Clarke, R .
CANCER RESEARCH, 2004, 64 (11) :4030-4039
[6]   Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines [J].
Concin, N ;
Zeillinger, C ;
Tong, D ;
Stimpfl, M ;
König, M ;
Printz, D ;
Stonek, F ;
Schneeberger, C ;
Hefler, L ;
Kainz, C ;
Leodolter, S ;
Haas, OA ;
Zeillinger, R .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 79 (01) :37-46
[7]   Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray [J].
Coser, KR ;
Chesnes, J ;
Hur, JY ;
Ray, S ;
Isselbacher, KJ ;
Shioda, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :13994-13999
[8]   Comparison of methods based on annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells [J].
Del Bino, G ;
Darzynkiewicz, Z ;
Degraef, C ;
Mosselmans, R ;
Fokan, D ;
Galand, P .
CELL PROLIFERATION, 1999, 32 (01) :25-37
[9]  
Dowsett M, 2003, CLIN CANCER RES, V9, p502S
[10]  
Ellis PA, 1997, INT J CANCER, V72, P608, DOI 10.1002/(SICI)1097-0215(19970807)72:4<608::AID-IJC10>3.0.CO